Aleniglipron (GSBR-1290)

Aleniglipron (GSBR-1290): Investigational Oral GLP-1 Medicine

Aleniglipron, also known as GSBR-1290, is an investigational once-daily oral small-molecule GLP-1 receptor agonist being developed by Structure Therapeutics for potential treatment of obesity, overweight and type 2 diabetes.

Unlike injectable GLP-1 medicines, aleniglipron is designed as an orally administered small molecule. Clinical development has progressed from Phase 2 studies into a Phase 3 programme evaluating its potential role in chronic weight management.

Important UK status: Aleniglipron is still an investigational medicine. It is not currently an authorised medicine for routine prescribing in the UK and should not be presented as an approved UK weight-loss or diabetes treatment.

What Is Aleniglipron?

Aleniglipron (GSBR-1290) is an orally available small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor.

It is being developed by Structure Therapeutics as a potential oral treatment for metabolic diseases, particularly obesity, overweight and type 2 diabetes.

The medicine is designed for once-daily oral administration, making it different from injectable GLP-1 receptor agonists such as semaglutide and tirzepatide.

How Does Aleniglipron Work?

Aleniglipron targets the GLP-1 receptor, a receptor involved in appetite regulation, food intake and glucose metabolism.

Structure Therapeutics describes aleniglipron as a selective, biased GLP-1 receptor agonist designed to preferentially activate G-protein signalling.

Through GLP-1 receptor activity, researchers are investigating whether aleniglipron can help reduce body weight and improve metabolic measures in people living with obesity, overweight or type 2 diabetes.

Aleniglipron and Weight Management Research

Aleniglipron is being investigated as a potential oral treatment for chronic weight management in adults with obesity or overweight and weight-related health conditions.

The Phase 2b ACCESS programme demonstrated dose-dependent reductions in body weight. In the ACCESS II study, Structure Therapeutics reported placebo-adjusted mean weight loss of up to 16.3% at 44 weeks at the 180 mg dose and 16.0% at the 240 mg dose.

These figures are clinical-trial results and should not be interpreted as guaranteed weight loss for an individual patient. The Phase 2 findings require confirmation through larger Phase 3 studies.

Aleniglipron Phase 3 Development

Aleniglipron has progressed into Phase 3 clinical development.

The ACCOMPLISH programme is evaluating once-daily oral aleniglipron for chronic weight management. ClinicalTrials.gov lists ACCOMPLISH-1 as a pivotal Phase 3 study involving adults with obesity or overweight and at least one weight-related comorbidity.

A second Phase 3 study, ACCOMPLISH-2, is evaluating aleniglipron in adults with obesity or overweight and type 2 diabetes.

The Phase 3 programme is designed to evaluate long-term efficacy, safety and tolerability over extended treatment periods.

Aleniglipron Clinical Trial Results

Earlier Phase 2 research provided evidence supporting continued development of aleniglipron.

In the Phase 2b ACCESS study, Structure Therapeutics reported placebo-adjusted mean weight loss of 11.3% at 36 weeks with the 120 mg dose.

Additional ACCESS II data reported placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg after 44 weeks.

The company also reported continued weight loss during an open-label extension, including up to 16.2% at 56 weeks with the 120 mg dose.

These findings come from clinical research and do not establish aleniglipron as an approved treatment.

Aleniglipron and Type 2 Diabetes

Aleniglipron is also being studied in people with type 2 diabetes who are living with overweight or obesity.

A Phase 2 study evaluated doses of aleniglipron up to 240 mg once daily in adults with type 2 diabetes and obesity or overweight. The study was designed to assess safety and tolerability as well as the potential effects of treatment.

A Phase 3 ACCOMPLISH study is now evaluating aleniglipron in adults with obesity or overweight and type 2 diabetes over a longer treatment period.

Is Aleniglipron Approved in the UK?

No. Aleniglipron is not currently authorised for routine prescribing in the UK.

It remains an investigational medicine undergoing clinical development. The fact that Phase 3 studies are underway does not mean that the medicine has received marketing authorisation.

UK regulatory status should be checked through the Medicines and Healthcare products Regulatory Agency (MHRA) before making any claims about future availability.

Can Aleniglipron Be Bought Online?

Aleniglipron should not be treated as an authorised UK medicine available for routine online purchase.

Products advertised online as aleniglipron, GSBR-1290 or research-grade GLP-1 products may not contain the claimed ingredient, dose or formulation.

Because the medicine remains investigational, consumers should be particularly cautious about websites offering unapproved versions or claiming that aleniglipron is already an established prescription weight-loss treatment.

Aleniglipron vs Semaglutide

Semaglutide is the active ingredient in authorised medicines such as Ozempic and Rybelsus.

Both semaglutide and aleniglipron act on the GLP-1 receptor, but they are chemically different medicines.

Aleniglipron is being developed as an oral small molecule, whereas semaglutide is a peptide medicine available in injectable and oral formulations depending on the product.

They should not be considered interchangeable without appropriate regulatory approval and clinical guidance.

Aleniglipron vs Mounjaro

Mounjaro (tirzepatide) is an authorised medicine in the UK for specific indications and acts on both GIP and GLP-1 receptors.

Aleniglipron is an investigational selective GLP-1 receptor agonist being developed as an oral small molecule.

The two medicines therefore have different pharmacological profiles and regulatory statuses.

Aleniglipron Safety and Side Effects

Because aleniglipron remains investigational, its final long-term safety profile and prescribing information have not yet been established.

Clinical studies have reported gastrointestinal adverse events consistent with effects commonly observed with GLP-1 receptor agonists. Structure Therapeutics has also reported improved tolerability in studies using a lower starting dose.

Clinical development continues to evaluate safety, tolerability, dosing and long-term outcomes.

Patients should not use an investigational medicine outside an appropriate clinical-trial or future authorised prescribing setting.

Aleniglipron Dose and Administration

Aleniglipron is being investigated as a once-daily oral medicine.

Clinical studies have evaluated multiple doses and titration approaches. However, investigational trial doses should not be interpreted as approved prescribing instructions.

There is currently no UK-approved aleniglipron dosing schedule for routine clinical use.

Why Is Aleniglipron Being Studied?

One of the potential advantages being investigated is an oral alternative to injectable GLP-1 receptor agonists.

An effective oral GLP-1 medicine could provide another treatment option for people who require pharmacological weight management or metabolic treatment, subject to successful clinical trials and regulatory approval.

However, convenience of administration alone does not establish effectiveness or safety. These questions are being evaluated through ongoing clinical research.

Important Information About Aleniglipron

• Aleniglipron is also known as GSBR-1290.
• It is an investigational oral small-molecule GLP-1 receptor agonist.
• It is being developed by Structure Therapeutics.
• It is designed for once-daily oral administration.
• It is being studied for obesity, overweight and type 2 diabetes.
• Phase 3 clinical development is underway.
• It is not currently authorised for routine prescribing in the UK.
• Clinical-trial results do not guarantee individual treatment outcomes.
• Unverified online products claiming to contain aleniglipron should not be used.

Frequently Asked Questions

What is aleniglipron?

Aleniglipron, also known as GSBR-1290, is an investigational once-daily oral small-molecule GLP-1 receptor agonist being developed for metabolic diseases including obesity and type 2 diabetes.

Is aleniglipron the same as GSBR-1290?

Yes. GSBR-1290 is the development code for aleniglipron.

Is aleniglipron approved in the UK?

No. Aleniglipron remains under clinical development and is not currently authorised for routine prescribing in the UK.

Is aleniglipron a GLP-1 medicine?

Yes. Aleniglipron is being developed as a selective GLP-1 receptor agonist.

Is aleniglipron an injection?

No. Aleniglipron is being developed as an orally administered small molecule designed for once-daily use.

Is aleniglipron the same as Ozempic?

No. Ozempic contains semaglutide, while aleniglipron is a separate investigational small-molecule GLP-1 receptor agonist.

Is aleniglipron the same as Mounjaro?

No. Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors. Aleniglipron is designed to activate the GLP-1 receptor.

Is aleniglipron available for weight loss?

Aleniglipron is being studied for chronic weight management, but it is not currently an authorised UK weight-loss medicine.

Can I buy aleniglipron online?

Aleniglipron remains investigational. Unverified products marketed online as aleniglipron or GSBR-1290 should not be used.

Key Product Information

Product	Aleniglipron / GSBR-1290
Developer	Structure Therapeutics
Drug type	Investigational small-molecule GLP-1 receptor agonist
Route under investigation	Oral administration
Frequency under investigation	Once daily
Research areas	Obesity, overweight and type 2 diabetes
Development stage	Phase 3
UK authorisation	Not currently authorised
Routine UK availability	Not authorised

Authoritative Resources

ClinicalTrials.gov – Aleniglipron ACCOMPLISH-1 Phase 3 Study

ClinicalTrials.gov – Aleniglipron ACCOMPLISH-2 Phase 3 Study

ClinicalTrials.gov – Aleniglipron Phase 2 Type 2 Diabetes Study

ClinicalTrials.gov – Aleniglipron ACCESS Phase 2b Study

Structure Therapeutics – Second Quarter 2026 Update

MHRA – Medicines and Healthcare products Regulatory Agency

Related Medicines

For information about other medicines in this area, explore Mounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (semaglutide), our weight-management medicines, our diabetes medicines or our health and medicine blog.

Medical disclaimer: This page is for educational purposes only. Aleniglipron/GSBR-1290 is an investigational medicine and is not currently authorised for routine use in the UK. It should not be used outside an appropriate clinical research or future authorised prescribing setting. Always seek advice from a qualified healthcare professional.